Results 11 to 20 of about 25,638 (254)
Clinical Epidemiology, 2022 Zeyu Xie, Sensen Yang, Weishang Deng, Jinjian Li, Jisheng Chen Key Specialty of Clinical Pharmacy, the First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, People’s Republic of ChinaCorrespondence: Jisheng Chen, Key Specialty of ...
Xie Z, Yang S, Deng W, Li J, Chen J
doaj +1 more source
Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model [PDF]
, 2013 Neurogenesis is a life long process, but the rate of cell proliferation and differentiation decreases with age. In Alzheimer's patients, along with age, the presence of Aβ in the brain inhibits this process by reducing stem cell proliferation and cell ...
Vadivel Parthsarathy +7 more
core +6 more sources
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis [PDF]
, 2012 Background Type 2 diabetes is a risk factor for Alzheimer's disease (AD), most likely linked to an impairment of insulin signalling in the brain. Therefore, drugs that enhance insulin signalling may have therapeutic potential for AD. Liraglutide (Victoza)
Hunter, Kerry +5 more
core +5 more sources
International Journal of Nanomedicine, 2017 Quan Qi,1,* Lei Lu,2,3,* Haiqing Li,1,* Zhize Yuan,1 Gaoxian Chen,2,3 Miao Lin,2,3 Zhengwen Ruan,4 Xiaofeng Ye,1 Zeyu Xiao,2,3,5 Qiang Zhao1 1Department of Cardiac Surgery, Rui Jin Hospital, 2Department of Pharmacology, Institute of Medical Sciences ...
Qi Q +9 more
doaj +1 more source
Potential of liraglutide in the treatment of patients with type 2 diabetes
Vascular Health and Risk Management, 2009 Carolyn F DeaconDepartment of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, DenmarkAbstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type ...
Carolyn F Deacon
doaj +1 more source
The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis [PDF]
, 2021 Glucocorticoid use may trigger secondary diabetes or exacerbate hyperglycemia in patients with diabetes mellitus (DM). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of patients with type 2 diabetes.
Zhang, Jiudan +4 more
core +1 more source
Investigation of the Metabolic Effects of Liraglutide on Patients with Overweight and Obesity [PDF]
, 2023 Obesity is a well-established risk factor for type 2 diabetes (T2D), a chronic metabolic disorder affecting millions worldwide. While lifestyle interventions such as diet and exercise are often the first-line treatment for obesity and T2D ...
Spencer, L.
core +1 more source
Diabetology & Metabolic Syndrome, 2021 Background Glucagon-like peptide-1 receptor (GLP-1R) activation may improve myocardial performance in the context of ischaemia, independent of glycaemic control, in individuals with and without type 2 diabetes mellitus.
Aung Myat +5 more
doaj +1 more source
Liraglutide improves pancreatic Beta cell mass and function in alloxan-induced diabetic mice. [PDF]
PLoS ONE, 2015 Glucagon-like peptide-1 (GLP-1) receptor agonists potentiate glucose-induced insulin secretion. In addition, they have been reported to increase pancreatic beta cell mass in diabetic rodents. However, the precise mode of action of GLP-1 receptor agonists
Kanako Tamura +5 more
doaj +1 more source
Liraglutide Attenuates Hepatic Ischemia–Reperfusion Injury by Modulating Macrophage Polarization
Frontiers in Immunology, 2022 Ischemia-reperfusion injury (IRI) is a common complication associated with liver surgery, and macrophages play an important role in hepatic IRI. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog primarily used to treat type 2 diabetes and obesity ...
Shang-Lin Li +22 more
doaj +1 more source